Loss-of-function mutation of REV1 (p.R704Q) mediates cetuximab primary resistance by activating autophagy in RAS-wild type metastatic colorectal cancer
Open Access
- 4 July 2024
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 598, 217103
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Freedom to err: The expanding cellular functions of translesion DNA polymerasesMolecular Cell, 2023
- Recent advances in targeting autophagy in cancerTrends in Pharmacological Sciences, 2023
- Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The complexity of p53-mediated metabolic regulation in tumor suppressionSeminars in Cancer Biology, 2022
- Inhibiting autophagy flux and DNA repair of tumor cells to boost radiotherapy of orthotopic glioblastomaBiomaterials, 2022
- Diagnosis and Treatment of Metastatic Colorectal CancerJAMA, 2021
- A Small Molecule Targeting Mutagenic Translesion Synthesis Improves ChemotherapyCell, 2019
- Repair, Reuse, Recycle: The Expanding Role of Autophagy in Genome MaintenanceTrends in Cell Biology, 2017
- Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategiesJournal of Molecular Medicine, 2014
- Comparative analysis of the mutagenic activity of oxaliplatin and cisplatin in the Hprt gene of CHO cellsEnvironmental and Molecular Mutagenesis, 2005